BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:27 PM
 | 
May 21, 2007
 |  BC Extra  |  Clinical News

Point Therapeutics down on talabostat hold

POTP fell $0.30 (68%) to $0.14 on Monday after FDA placed the company's talabostat (PT-100) development program on hold. The inhibitor of fibroblast activation protein (FAP), dipeptidyl peptidase-8 (DPP-8) and DPP-9...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >